Company intelligence / Profile preview

DIANA Biotechnologies

Vestec, Středočeský kraj, Czech Republicdianabiotech.com ↗

Ownership: Private
Employees: ~75
Development stage: Commercial

Overview

DIANA Biotechnologies became the largest producer of COVID‑19 PCR tests in Czechia during the pandemic, supplying over 40% of national demand. Their tests were highly sensitive and enabled high-throughput detection of all major virus variants. The company has since reinvested profits into expanding R&D across molecular diagnostics, monoclonal antibody development, and drug discovery services. No clinical-stage therapeutics reported as of May 2025; main commercial products are diagnostic kits.

Therapeutic areas: OtherInfectious Diseases
Modalities: PCR-based diagnostics (molecular diagnostics)Monoclonal antibodiesSmall molecules (drug discovery)Oligonucleotides (custom synthesis)
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on DIANA Biotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DIANA Biotechnologies.

Explore the full profile